In 1938, at the Sandoz laboratories in Basel, Albert Hofmann synthesized LSD-25, a molecule derived from ergot, a parasitic fungus that infects certain grasses. A few years later, while resuming his study of the substance, the Swiss chemist accidentally came into contact with a small amount of LSD, experiencing dizziness and kaleidoscopic visions.
Realizing its psychotropic potential, Hofmann voluntarily ingested 250 µg - which he considered a minimal dose - and extensively tested its effects on his bike ride home from the lab. After moments of intense anxiety, the experience gave way to persistent visions of shapes and colors.
Those early experiences sparked a scientific interest that led, in the years that followed, to the study of LSD in the field of psychiatry as well. This period of research was interrupted by the spread of recreational use of the substance, the progressive restrictions introduced beginning in the 1960s, and finally its inclusion among internationally controlled substances.
Decades later, research on psychedelics has resumed. Switzerland has played a special role in this rediscovery, and today - subject to authorization by the FOPH and for selected patients - some of these substances may be used in highly controlled clinical settings. Research is exploring their potential in various fields, from psychiatry to palliative care, even in cases where conventional treatments have yielded limited results.
However, one point must be emphasized: these substances do not constitute therapy on their own, but rather support it. The administration of substances such as LSD, psilocybin, or MDMA takes place within a process that includes patient preparation, guidance during the experience, and a subsequent phase of integrating the experience.
This is why we refer to “psychedelic-assisted therapies.” The order of the words is not random but crucial.
We discuss this with:
Lara Pellizzari, SUPSI lecturer in the field of mental health and psychiatry, director of the DAS in Mental Health and Psychiatry and of the CAS in Psychedelic-Assisted Therapy.
Veronica Paggi, nurse and SUPSI lecturer in continuing education, active in programs dedicated to palliative care and oncology, and director of the CAS in Psychedelic-Assisted Therapy.
Benedetto Zefiro Mellacqua, medical director of the Mendrisio Cantonal Psychiatric Clinic, psychiatrist, and psychotherapist.